Transaction DateRecipientSharesTypePriceValue
3rd February 2020Jerry J Jasinowski526,316Grant/award etc.$0.19$100,000.04
27th January 2020Linda F Powers220,000Open or private sale$4.60$1,012,000.00
3rd June 2019Linda F Powers10,000Open or private purchase$6.00$60,000.00
8th May 2019Linda F Powers61,667Open or private purchase$9.00$555,003.00
28th December 2018Linda F Powers804,146Open or private sale$0.17$136,704.82
27th December 2018Linda F Powers3,558,639Open or private sale$0.17$604,968.63
Northwest Biotherapeutics
Northwest Biotherapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Northwest Biotherapeutics, Inc. is a clinical stage biotechnology company. The firm engages in the development of cancer vaccines designed to treat solid tumor cancers. It also offers a platform technology for DCVax dendritic cell-based vaccines.

Ticker: NWBO
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1072379
Employees: 17
Exchange: US OTC
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $6 M (0%)
Assets, Current: $8 M (156%)
Property, Plant and Equipment, Net: $157 Th (-44%)
Other Assets, Noncurrent: $755 Th (-5%)
Assets: $15 M (63%)
Liabilities, Current: $89 M (115%)
Liabilities: $96 M (82%)
Common Stock, Value, Issued: $722 Th (17%)
Common Stock, Shares, Issued: $722 (-99%)
Additional Paid in Capital, Common Stock: $812 M (2%)
Retained Earnings (Accumulated Deficit): $895 M (6%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $2 M (91%)
Stockholders' Equity (Parent): $81 M (0%)
Liabilities and Equity: $15 M (63%)
Research and Development: $3 M (-54%)
General and Administrative Expenses: $3 M (-55%)
Operating Income/Loss: $7 M (-50%)
EPS (basic): $0.08 (0%)
EPS (diluted): $0.08 (0%)